SGLT2 inhibitors and cardiorenal protection Hermes Toros Xavier, Rafael de Souza Pinto

Abstract

SGLT2 inhibitors, potent glycosurics used in glycemic control in diabetic patients, are another example of drugs that began their clinical journey with a specific therapeutic indication and ended up evolving into other treatment spectrums. SGLT2 inhibitors demonstrated a significant benefit, representing a class effect in preventing the specific outcome of hospitalizations for HF. This Short Note presents a growing body of evidence supporting the use of SGLT2 inhibitors as adjuvant therapy in HF and CKD, even in the absence of diabetes.